EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
Key facts
- Who runs it
- University of Utah
- Where
- Murray, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 10 people enrolled
- Started
- 20 Jan 2022
- Ended
- 1 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- EDTA
- Abreva
- Record updated
- 31 October 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- To be eligible for enrollment, a subject must meet the following criteria:
- Understands the requirements of the study and provides written informed consent prior to undergoing any study-related procedures
- Subject is a male or female between the ages of 18-65 years old, inclusive
- Fitzpatrick skin type II or III
- History of at least one year of herpes labialis induced by UV exposure
- Able to recall exact location of most common or most recent outbreak
- History of at least 50% of cold sore outbreaks occurring with UV (sun) exposure
- At least 1 HSV-1 outbreak within the past 12 months
- Experiences prodromal symptoms before HSV-1 outbreaks
- Subject is willing and able to comply with protocol-specified dosing, visits to the clinic and tracking of pain
Who cannot take part
- Outbreak <2 weeks prior to enrollment
- On any systemic or topical steroid, immune suppressant or chemotherapeutic agent within the past 30 days
- Use of tanning beds, history of sunburn, or beach vacation <2 weeks prior to enrollment
- Current immunosuppressed state due to underlying disease (i.e. HIV infection) concomitant treatment (i.e. chemotherapy)
- Previously treated with EED
- Alcohol or drug abuse
- History of herpes simplex vaccine
- History of photosensitivity, lupus erythematosus, or current use of photosensitizing medication
- Current upper respiratory tract infection or any active illness that could trigger cold sores or affect overall health of the patient or the assessment of the study agent
- Abnormal skin conditions in the area of the recurrent HSV1 outbreaks
- Subjects will be excluded from the study if they meet any of the following criteria:
- On antiviral suppression within the past 30 days
- Requires more than acetaminophen for pain from recurrent HSV outbreaks
- Pregnant or intending to become pregnant during the study
- Enrolled in another clinical trial within the past 30 days
- On any analgesics or NSAIDs that cannot be stopped during the study
Where in United States
- University of Utah Midvalley DermatologyMurray, United States
About the trial
What the trial wants to find out
This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 20 subjects with documented herpes labialis. Patients will be treated with the study drug, EDTA Eye Drops or the active comparator of Abreva.
Read full original descriptionShow less
Potential subjects will be assessed during a screening visit that must take place no greater than 2 weeks prior to the Day 1 (Baseline) visit. During the screening period, subjects that meet all other entry criteria will undergo UV susceptibility testing to determine their individual MED (minimal erythemal dose). UV susceptibility testing takes place over two days with exposure to UV light on specified regions on the subject's back followed by an assessment of the exposed areas 24 hours later to identify the MED. Subjects who have a measurable MED will be allowed to enroll in the study. Each subject will be randomly assigned in a 1:1 ratio to receive either EED or Comparator.
Patients who express a cold sore will track the lesion with a diary card to rate their pain levels, and any unusual symptoms at Day 1, Day 3, Day 5, Day 7, and Day 10. Patients may also take photographs of the lesion throughout the study.
The 2 groups in the trial
- Study Drug (EDTA Eye Drops)Treatment being tested
Patients will treat herpes simplex eruption with EDTA eye drops.
Treatment: EDTA
- Active Comparator (Abreva)Existing treatment, for comparison
Patients will treat herpes simplex eruption with Abreva.
Treatment: Abreva
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Efficacy Assessor-Blinded, Study to Assess Preliminary Efficacy and Safety of EDTA Eye Drops v. an Active Comparator in the Suppression of Herpes Simplex Virus Eruptions in Subjects With a History of Herpes Labialis
- Record updated
- 31 October 2025